Literature DB >> 2870368

(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.

F J Grandas Perez, P G Jenner, M Nomoto, S Stahl, N P Quinn, J D Parkes, P Critchley, C D Marsden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2870368     DOI： 10.1016/s0140-6736(86)91004-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.

Authors:  W Poewe; L Schelosky; B Kleedorfer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

2.  (+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.

Authors:  N M Rupniak; S Boyce; M J Steventon; S D Iversen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

3.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.

Authors:  C M Gust; S K Hemrick-Luecke; R W Fuller
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  Binding of (+)PHNO and other D2-dopamine agonists to D1-dopamine receptors labelled by [3H]SCH 23390.

Authors:  D J Pettibone; J A Totaro; B V Clineschmidt
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.